Endpoint definition
↥| Name | L12_PEMPHIKELA |
|---|---|
| Long name | Severe bullous disorders, KELA reimbursement |
| KELA reimboursements codes | 135 |
| Level in the ICD-hierarchy | 3 |
| First defined in version | DF2 |
Severe bullous disorders, KELA reimbursement
vesiculobullous skin disease: Skin diseases characterized by local or general distributions of vesicles and bullae (i.e. blisters). Both vesicles and bullae are fluid-filled lesions, distinguished by size (vesicles being less than 5–10 mm and bullae being larger than 5–10 mm). Vesiculobullous diseases are classified according to the site and mode of blister formation. Lesions can appear spontaneously or be precipitated by infection, trauma, or sunlight. Etiologies include immunologic and genetic factors. In the case of vesiculobullous diseases which are also immune disorders, the term immunobullous is sometimes used. (From Scientific American Medicine, 1990, and Wikipedia)
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 22 | 11 | 11 |
| Unadjusted prevalence (%) | 0.01 | 0.01 | 0.01 |
| Mean age at first event (years) | 59.69 | 59.55 | 59.82 |
| Case fatality at 5-years (%) | 9.09 | 9.09 | 9.09 |
Longitudinal metrics
| All | Female | Male | |
|---|---|---|---|
| Median nb. of events per indiv. | 1.0 | 1.0 | 1.0 |
| Recurrence at 6 months (%) | - | - | - |
Survival analyses between endpoints
↥Plot
before Severe bullous disorders, KELA reimbursement
after Severe bullous disorders, KELA reimbursement
Loading survival analyses plot…
Table
Loading survival analyses table…